A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors

INTRODUCTION: TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including antimetabolite and alkylating agents. TRC102 rapidly and covalently binds to apurinic/apyrimidinic (AP) sites generated during BER, and TRC102-bound DNA causes topoisomerase II-dependen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Invest New Drugs
Hauptverfasser: Gordon, Michael S., Rosen, Lee S., Mendelson, David, Ramanathan, Ramesh K., Goldman, Jonathan, Liu, Lili, Xu, Yan, Gerson, Stanton L., Anthony, Stephen P., Figg, William D., Spencer, Shawn, Adams, Bonne J., Theuer, Charles P., Leigh, Bryan R., Weiss, Glen J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2012
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6662598/
https://ncbi.nlm.nih.gov/pubmed/23054206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9876-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge